N-terminal pro-B-type natriuretic peptide testing in patients presenting to the Emergency Department With acute dyspnoea: evaluation of effects on treatment, hospitalisation rate and costs
| ISRCTN | ISRCTN28653133 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN28653133 |
| Protocol serial number | NL931 (NTR956) |
| Sponsor | Erasmus Medical Centre (The Netherlands) |
| Funder | Erasmus Medical Centre (The Netherlands) - Mrace Committee |
- Submission date
- 30/05/2007
- Registration date
- 30/05/2007
- Last edited
- 25/10/2021
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Respiratory
Plain English summary of protocol
Not provided at time of registration
Contact information
Scientific
Erasmus Medical Centre
Rotterdam
3015 CE
Netherlands
| Phone | +31 (0)10 4639222 |
|---|---|
| j.rutten@erasmusmc.nl |
Study information
| Primary study design | Interventional |
|---|---|
| Study design | Randomised, single blinded, controlled, parallel group trial |
| Secondary study design | Randomised controlled trial |
| Scientific title | N-terminal pro-B-type natriuretic peptide testing in patients presenting to the Emergency Department With acute dyspnoea: evaluation of effects on treatment, hospitalisation rate and costs |
| Study objectives | Diagnostic uncertainty in patients with complaints of shortness of breath presenting to the Emergency Department of a hospital may delay treatment and proper care. In patients with shortness of breath due to heart failure increased plasma levels of NT-pro-B-type natriuretic peptide (NT-proBNP) can be demonstrated. The use of NT-proBNP as a biomarker for heart failure in patients presenting to the Emergency Department with dyspnoea might improve care and reduce length of hospital stay. In our study we will investigate the effect of introduction of NT-proBNP as biomarker for heart failure on treatment, time to discharge and costs. |
| Ethics approval(s) | Received from the Medical Ethics Review Comittee Erasmus MC on the 13th October 2004 (ref: MEC-2004-201). |
| Health condition(s) or problem(s) studied | Cost-effectiveness, dyspnoea, amino-terminal pro B-type natriuretic peptide |
| Intervention | Study-group: Measurement of NT-proBNP plasma level at presentation in the Emergency Department. Control-group: No measurement of NT-proBNP plasma level at presentation in the Emergency Department. Blood was collected for determination of NT-proBNP levels at the end of the study. |
| Intervention type | Other |
| Primary outcome measure(s) |
1. Time to discharge, measured at discharge from hospital |
| Key secondary outcome measure(s) |
1. Duration of stay at the Emergency Department, measured at discharge from the Emergency Department |
| Completion date | 05/01/2008 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Sex | Not Specified |
| Target sample size at registration | 477 |
| Key inclusion criteria | 1. Age 18 years or older 2. Acute dyspnoea as the most prominent complaint |
| Key exclusion criteria | 1. Acute dyspnoea due to a trauma 2. Acute dyspnoea due to cardiogenic shock 3. Renal failure requiring dialysis |
| Date of first enrolment | 12/01/2004 |
| Date of final enrolment | 05/01/2008 |
Locations
Countries of recruitment
- Netherlands
Study participating centre
3015 CE
Netherlands
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|---|
| IPD sharing plan summary | Not provided at time of registration |
| IPD sharing plan | Not provided at time of registration |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | 01/07/2008 | 25/10/2021 | Yes | No |
Editorial Notes
25/10/2021: Publication reference added.
